CONTACT

CONTACT

CONTACT

mail : unite-reads(at)unige.ch

Vincent Jaquet, PhD
Dept. of Pathology and Immunology
Vincent Jaquet
Tel :022.37.94136

Vincent Jaquet holds a PhD in Molecular Biology from the University of Lausanne.
He has both industrial and academic experience. He is currently "collaborateur scientifique" at the Faculty of Medicine. He specialized during the last 10 years in the pharmacology of NOX enzymes and the identification and characterization of small molecules NOX inhibitors.

Yves Cambet, MSc
Dept. of Pathology and Immunology
Yves Cambet
Tel :022.37.94046

Yves Cambet obtained his Master at University of Geneva.
He has more than 20 years industrial expertise in high-throughput screening of small molecules. He worked as screening scientist for several pharmaceutical companies (Glaxo, Serono, Merckserono and Inventiva). He puts now his extensive experience to the service of the researchers of the Faculty of Medicine.

 

Selected publications:

 1. Bedard K, Whitehouse S, Jaquet V. Challenges, progresses and promises for developing future NOX therapeutics. Antioxid Redox Signal. 2015 Jul 24.

 2. Hirano K, Chen WS, Chueng AL, Dunne AA, Seredenina T, Filippova A, Ramachandran S, Bridges A, Chaudry L, Pettman G, Allan C, Duncan S, Lee KC, Lim J, Ma MT, Ong AB, Ye NY, Nasir S, Mulyanidewi S, Aw CC, Oon PP, Liao S, Li D, Johns DG, Miller ND, Davies CH, Browne ER, Matsuoka Y, Chen DW, *Jaquet V, *Rutter RA (*equal contribution). Discovery of GSK2795039, a novel small molecule NADPH oxidase 2 inhibitor. Antioxid Redox Signal. 2015 Jul 2.

 3. Seredenina T, Chiriano G, Filippova A, Nayernia Z, Mahiout Z, Fioraso-Cartier L, Plastre O, Scapozza L, Krause KH, Jaquet V. A subset of N-substituted phenothiazines inhibits NADPH oxidases. Free Radic Biol Med. 2015 May 23; 86:239-249.

 4. Jaquet V, Marcoux J, Forest E, Leidal KG, McCormick S, Westermaier Y, Perozzo R, Plastre O, Fioraso-Cartier L, Diebold B, Scapozza L, Nauseef WM, Fieschi F, Krause KH, Bedard K. NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. Br J Pharmacol. 2011 Sep;164(2b):507-20.

 5. Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal. 2009 Oct;11(10):2535-52.